OBJECTIVE: To evaluate the therapeutic effects of Guliu capsule (GLC) combined with 89Sr in treating metastatic bone tumors. METHODS: On the basis of random sampling and grouping, 50 patients with metastatic bone tumors were selected to receive combined treatment with GLC and (89)Sr with another 50 patients recruited for (89)Sr treatment alone. The therapeutic effect of the therapies were evaluated according to the relief of ostalgia and quality-of life (QOF), local bone metabolism and hematopoietic function of the bone marrow. RESULTS: The efficacy rate of GLC+89Sr and (89)Sr in relieving ostalgia was 94.0% and 76.0%, and the rate of QOF improvement and stabilization was 94.0% and 74.0%, respectively, both showing significant difference between the two groups (P<0.05). The effect of the two treatment protocols on local bone metabolism and their hemotoxicity were also significantly different (P<0.05, P<0.01, respectively). CONCLUSION: Combined treatment with GLC and (89)Sr is effective for metastatic bone tumor and improves the patient's QOF with enhanced ostalgia relief rate and decreased hemotoxicity.
RCT Entities:
OBJECTIVE: To evaluate the therapeutic effects of Guliu capsule (GLC) combined with 89Sr in treating metastatic bone tumors. METHODS: On the basis of random sampling and grouping, 50 patients with metastatic bone tumors were selected to receive combined treatment with GLC and (89)Sr with another 50 patients recruited for (89)Sr treatment alone. The therapeutic effect of the therapies were evaluated according to the relief of ostalgia and quality-of life (QOF), local bone metabolism and hematopoietic function of the bone marrow. RESULTS: The efficacy rate of GLC+89Sr and (89)Sr in relieving ostalgia was 94.0% and 76.0%, and the rate of QOF improvement and stabilization was 94.0% and 74.0%, respectively, both showing significant difference between the two groups (P<0.05). The effect of the two treatment protocols on local bone metabolism and their hemotoxicity were also significantly different (P<0.05, P<0.01, respectively). CONCLUSION: Combined treatment with GLC and (89)Sr is effective for metastatic bone tumor and improves the patient's QOF with enhanced ostalgia relief rate and decreased hemotoxicity.